Form 4: Apeiron Investment Group Boosts Stake in ATAI Life Sciences

Apeiron Investment Group significantly increased its holdings in ATAI Life Sciences through a recent purchase of shares.

Summary

• Apeiron Investment Group Ltd., a 10% owner of ATAI Life Sciences N.V., purchased 10,835,718 common shares.
• The transaction was executed on February 14, 2025, at a price of $2.1 per share.
• Following this transaction, Apeiron Investment Group Ltd. directly owns 40,555,215 shares.
• Apeiron also indirectly owns 1,799,302 shares through Apeiron Presight Capital Fund II, L.P.

Sentiment

Score: 7

Explanation: The sentiment is positive, reflecting a substantial investment by a major shareholder, suggesting confidence in the company.

Positives

• The increased investment by Apeiron Investment Group could be seen as a strong vote of confidence in ATAI Life Sciences' future prospects.

Negatives

• The document does not provide context for the investment, making it difficult to assess the long-term implications fully.

Risks

• The document does not detail any risks.

Future Outlook

The document does not contain any explicit forward-looking statements.

Industry Context

This transaction represents a significant investment within the biotechnology sector, specifically in a company focused on mental health treatments.

Comparison to Industry Standards

• It is difficult to compare to industry standards as it is a single transaction. Further information on ATAI's financials and performance would be needed for a full comparison.

Related Party Transactions

• The purchase of shares by Apeiron Investment Group Ltd., a 10% owner, is a related party transaction.

Stakeholder Impact

• Shareholders may view this increased investment as a positive signal.
• The impact on other stakeholders is not detailed.

Key Dates

Keywords

ATAI Life Sciences, Apeiron Investment Group, Stock Purchase, Beneficial Ownership, Investment, Securities, Common Shares, Section 16(a), Christian Angermayer